title: Does gender matter in glioblastoma?
abstract: BACKGROUND The clinical outcome of glioblastoma (GBM) patients who receive radiotherapy alone or with chemotherapy is well established. However, little is known about how many patients do not receive this treatment. We consider it is important to investigate why a proportion of operated patients do not receive further treatment after surgery. METHODS We reviewed all consecutive GBM patients operated on in our hospital between January 2000 and December 2008. RESULTS A total of 216 patients with GBM were identified. Fifty-five (25%) did not receive any treatment after surgery. Univariate analysis showed that factors associated with no further treatment after surgery were older than 60 years (p=0.002), of female gender (p=0.03), had a KPS<70 (p<0.001) and had had a biopsy (p<0.001). Multivariate analysis indicated that age =60 years and KPS <70 were independent predictors of no further treatment after surgery. Gender was not an independent variable. However, women in the whole series were older than 60 years (p=0.01), and they had a worse KPS (p=0.02) and more biopsies (p=0.04) than men. In the whole group, median survival time was 10.4 months for men (n=125) vs. 7.2 months for women (n=91), log rank p<0.04. This difference was not observed in the group that was treated after surgery. CONCLUSIONS One out of four patients could not be treated after surgery. Independent predictors were older age and low KPS. These poor risk variables were more frequent in women and their survival was therefore lower than men in our series.
authors.affiliation: Institute of Haematology and Oncology, Department of Radiation Oncology, Hospital Clínic, University of Barcelona, Spain. everger@clinic.ub.es
authors.forename: E
authors.initials: E
authors.lastname: Verger
authors.forename: I
authors.initials: I
authors.lastname: Valduvieco
authors.forename: Ll
authors.initials: L
authors.lastname: Caral
authors.forename: T
authors.initials: T
authors.lastname: Pujol
authors.forename: T
authors.initials: T
authors.lastname: Ribalta
authors.forename: N
authors.initials: N
authors.lastname: Viñolas
authors.forename: T
authors.initials: T
authors.lastname: Boget
authors.forename: L
authors.initials: L
authors.lastname: Oleaga
authors.forename: Y
authors.initials: Y
authors.lastname: Blanco
authors.forename: F
authors.initials: F
authors.lastname: Graus
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000401:mortality* / Q000601:surgery / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005909:Glioblastoma / Q000401:mortality* / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant; D012737:Sex Factors; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult